Skip to content

Ketamine and psychedelic-assisted therapy: all studies

Page 7 of 9: studies 61 to 70 of 88, newest first. Back to the ketamine and psychedelic-assisted therapy overview

Research

Ketamine-Assisted Psychodynamic Psychotherapy.

Psychodynamic psychiatry December 1, 2023 John G Cottone

This case report details the treatment of a longtime psychodynamic psychotherapy patient, with a particular focus on a ketamine-assisted psychotherapy (KAP) session, and how the progress achieved during this session compares with the literature on KAP. The patient is a 54-year-old woman with a history of multiple traumas, including sexual assault and life-threatening physical injuries, as well...

Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.

Journal of Palliative Medicine October 1, 2023 Noah D Gold, Austin J. Mallard, Jacob C Hermann et al. 5 citations

Background: Amyotrophic lateral sclerosis (ALS) is an aggressive, terminal neurodegenerative disease that causes death of motor neurons and has an average survival time of 3-4 years. ALS is the most common motor neuron degenerative disease and is increasing in prevalence. There is a pressing need for more effective ALS treatments as available pharmacotherapies do not reverse disease progression...

The need for establishing best practices and gold standards in psychedelic medicine.

Journal of Affective Disorders July 1, 2023 Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price et al. 38 citations

Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...

Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study.

Psychopharmacology July 1, 2023 Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin et al. 26 citations

Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression. The phenomenology of ketamine-induced experiences and their relation to its psychotherapeutic potential have not yet been systematically investigated. To describe the phenomenology of patient experiences during oral esketamine treatment for...

Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression: A Patient With Lifelong Self-Doubt and Self-Criticism.

The Journal of Clinical Psychiatry April 5, 2023 Albert Yeung, Guy Sapirstein, Laura D Crain et al.

Although consensus in the field is lacking, the most common definition for treatment-resistant depression (TRD) requires a minimum of 2 prior treatment failures with confirmed adequate dose and duration. This article presents a clinical example of TRD in a patient with a long history of depression and inadequate response to treatment. The prominent feature is the patient's persistent...

Ketamine-assisted psychotherapy provides lasting and effective results in the treatment of depression, anxiety and post traumatic stress disorder at 3 and 6 months: Findings from a large single-arm retrospective effectiveness trial

medRxiv January 17, 2023 Ryan Yermus, Michael Verbora, Sidney H. Kennedy et al. 2 citations preprint

Abstract IMPORTANCE Ketamine-Assisted Psychotherapy (KAP) is an emerging treatment option to alleviate treatment resistant affective disorders, but its long term effectiveness remains unclear. OBJECTIVE To examine the treatment effects of KAP on anxiety, depression, and post traumatic stress disorder (PTSD) at 1, 3, and 6 months post treatment. DESIGN, SETTING, AND PARTICIPANTS This...

Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review.

Frontiers in Psychiatry 2023 Emily Whinkin, Therry Rose J Eparwa, Michelle C Julseth et al.

Assess changes in symptoms of anxiety, depression, and psychosocial or spiritual distress before and after ketamine-assisted psychotherapy (KAP) in individuals with problematic substance use (PSU). A retrospective chart review was performed on participant data from two five-year prospective outcomes studies: the AIMS Medical Outcomes Study (AMOS) and the AIMS Cancer Outcomes Study (ACOS). The...

Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses.

Frontiers in Psychiatry 2023 Philip E. Wolfson, Julane Andries, Daniel Ahlers et al. 27 citations

Ketamine-assisted psychotherapy is a promising new treatment for a variety of mental disorders of adolescence. There is currently an adolescent mental health crisis, with a high prevalence of disorders, diagnostic complexity, and many adolescents failing to respond to conventional treatments. While there is strong evidence for the use of ketamine in adults for a variety of treatment-refractory...

Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches.

Frontiers in pain research (Lausanne, Switzerland) 2023 Daniella Batievsky, Michelle Weiner, Shari B Kaplan et al. 8 citations

Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature. This paper reports the findings of an observational preliminary study that explored the efficacy of ketamine-assisted psychotherapy (KAPT) for chronic pain/major...

The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?

Cureus October 31, 2022 Arafath Mohamed, Shehla Touheed, Muzammil Ahmed et al. 11 citations

Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is psychotherapy, according to current treatment guidelines. However, PTSD continues to be a chronic condition even after psychotherapy, with high psychiatric and medical illness rates. There is a dire need...